SBFM

Sunshine is a Canada-only generic drug seller (via Nora Pharma) with a genuine but structurally low-quality business. Revenue is real at $36.3M, yet growth has collapsed from acquisition-driven triples to just +4.1% YoY, and gross margin sits at only 33.8% — management itself warns generics are 'significantly less profitable than innovative medicines' and that revenue is 'heavily dependent on federal and provincial reimbursement frameworks' where 'pricing pressures in Canada represent the highest risk.' The company has never been profitable: a $5.98M net loss in FY2025 (worse than FY2024's $5.13M) against a $75.0M accumulated deficit, a -17.2% operating margin and -25.9% ROE. R&D was cut 35% to a token $604K, so this is a stagnant distributor, not a growth biotech.

The decisive problem is shareholder value destruction through dilution. Shares outstanding jumped 81.2% in a single year as the company repeatedly issued stock — 127K, 660K and 1.19M shares in early 2025 alone via warrant exercises and a registered direct offering — to fund an operation that still burns cash (-$5.33M operating cash flow). MD&A is explicit: 'We have no committed sources of capital and we anticipate that we will need to raise additional capital... Additional capital may not be available on terms acceptable to us, or at all,' with existing cash covering only ~18 months. Even as the business inches toward breakeven, holders are diluted faster than book value can compound.